HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Muíño, Coralia Bueno; Martín, Miguel; Monte-Millán, Marı́a del; García-Sáenz, José Á.; López-Tarruella, Sara

doi:10.3390/cancers14030512

Cited by 3 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Approximately 15%-20% of BC patients experience HER2 overexpression or gene amplification, and HER2-positive (HER2+) BC is more invasive compared to HER2-negative BC. 3,4 The emergence of anti-HER2 agents has provided new hope for treating HER2+ BC patients.…”

Section: Introductionmentioning

confidence: 99%

“…Following homodimerization or heterodimerization, HER2 initiates downstream tyrosine kinase signaling cascades, thereby influencing cell proliferation, migration, invasion, tumor growth, and metastasis 2 . Approximately 15%–20% of BC patients experience HER2 overexpression or gene amplification, and HER2‐positive (HER2+) BC is more invasive compared to HER2‐negative BC 3,4 . The emergence of anti‐HER2 agents has provided new hope for treating HER2+ BC patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Chen,

Yang,

2024

Intl Journal of Cancer

View full text Add to dashboard Cite

Anti‐human epidermal growth factor receptor 2 (HER2) agents have exhibited pronounced tumor‐inhibitory activity, yet the accompanying ocular toxicity has frequently been underestimated. We aim to conduct a comprehensive comparative analysis of ocular toxicity risk related to various anti‐HER2 agents. We executed a retrospective pharmacovigilance investigation based on the FDA Adverse Event Reporting System (FAERS) database, covering the period from Q2 2018 to Q1 2023. The disproportionality analysis was performed to assess ocular toxicity risk. Multivariate logistic regression was implemented to mitigate potential biases. Moreover, the time to onset of ocular toxicity was also evaluated. A total of 3467 ocular adverse event (AE) reports concerning anti‐HER2 agents were collected. At the preferred term (PT) level, there were 69 positive signals, among which excessive eye blinking, abnormal sensation in the eye, and asthenopia presented a significant risk. In comparison to tyrosine kinase inhibitors (TKIs), antibody drugs were associated with a broader range of ocular disorders at Standardized MedDRA Queries (SMQ)levels, including conjunctival disorders, corneal disorders, ocular infections, ocular motility disorders, optic nerve disorders, and retinal disorders. In terms of onset time, pertuzumab displayed an earlier onset at 21.5 days, while trastuzumab deruxtecan had the latest at 91.5 days. In summary, our study reveals varying degrees of ocular toxicity related to anti‐HER2 agents, with a significantly higher risk observed in antibody drugs. Additionally, novel ocular toxicity signals, not documented in product labels, have been detected. In the future, further research will be necessary to validate our findings.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Chen,

Yang,

2024

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition

Elkafoury,

El-Hamamsy,

El-Bastawissy

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Breast Cancer Priorities in Limited-Resource Environments: The Price-Efficacy Dilemma in Cancer Care

Al-Sukhun¹,

Tbaishat

Hammad

2022

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

Breast cancer has become one of the leading causes of morbidity and mortality in low- and middle-income countries, where 62% of the world’s total new cases are diagnosed. Therefore, the productivity loss because of premature death resulting from female breast cancer is also on the rise. The major challenge in low- and middle-income countries is to reduce the proportion of women presenting with advanced-stage disease, a challenge unlikely to be overcome by adoption of expensive national mammography screening programs. Awareness and education campaigns should focus not only on patients and societies but also on policy makers to address and optimize breast cancer care. Adaptation of existing guidelines and prioritization according to local resources are essential to address the unique needs and overcome the unique barriers of each society to facilitate practical implementation and improve outcomes. Emphasis on the principle of a cancer groundshot in addressing value in cancer care is vital to improving access to therapies that are proven to work rather than chasing after new drugs or innovations of doubtful or marginal clinical benefit. Until we have drug-pricing interventions that take into account the local income of each society, we must acknowledge the fact that the delivery of cancer care will never be the same all around the world.

show abstract

HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cited by 3 publications

References 74 publications

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database

Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition

Breast Cancer Priorities in Limited-Resource Environments: The Price-Efficacy Dilemma in Cancer Care

Contact Info

Product

Resources

About